Co-targeting of vascular integrity and pro-angiogenic, innate immune cells by angiogenic inhibitors (VEGF, Ang-2) already showed improved therapeutic efficacy in GBM models [90, 106, 110]. The gene discussed is VEGFA; the disease is glioblastoma.